Barbara Vogg
Overview
Explore the profile of Barbara Vogg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
231
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vogg B, Poetzl J, Schwebig A, Sekhar S, Kivitz A, Krivtsova N, et al.
Clin Ther
. 2024 Sep;
46(11):916-926.
PMID: 39294041
Purpose: Sandoz biosimilar denosumab (GP2411 [SDZ-deno]; Jubbonti/Wyost) is approved by the US FDA, EMA and Health Canada for all indications of reference denosumab (REF-deno; Prolia/Xgeva), a fully human IgG2κ monoclonal...
2.
Jeka S, Dokoupilova E, Kivitz A, Zuchowski P, Vogg B, Krivtsova N, et al.
J Bone Miner Res
. 2024 Mar;
39(3):202-210.
PMID: 38477751
Denosumab is a monoclonal antibody used to reduce risk of fractures in osteoporosis. ROSALIA was a multicenter, double-blind, randomized, integrated phase I/phase III study comparing the efficacy, pharmacokinetics (PK), pharmacodynamics...
3.
Vogg B, Poetzl J, El Galta R, Fuhr R, Schwebig A, Sekhar S
Expert Opin Biol Ther
. 2024 Jan;
24(1-2):91-100.
PMID: 38269652
Background: This Phase I study compared the pharmacokinetic (PK) and pharmacodynamic (PD) similarity of GP2411 proposed denosumab biosimilar to reference denosumab (a monoclonal antibody for specific pro-resorptive conditions). Research Design...
4.
Mainolfi N, Ehara T, Karki R, Anderson K, Mac Sweeney A, Liao S, et al.
J Med Chem
. 2020 Feb;
63(11):5697-5722.
PMID: 32073845
The alternative pathway (AP) of the complement system is a key contributor to the pathogenesis of several human diseases including age-related macular degeneration, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic...
5.
Neumann U, Ufer M, Jacobson L, Rouzade-Dominguez M, Huledal G, Kolly C, et al.
EMBO Mol Med
. 2018 Sep;
10(11).
PMID: 30224383
The beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1) initiates the generation of amyloid-β (Aβ), and the amyloid cascade leading to amyloid plaque deposition, neurodegeneration, and dementia in Alzheimer's disease (AD)....
6.
Neumann U, Rueeger H, Machauer R, Veenstra S, Lueoend R, Tintelnot-Blomley M, et al.
Mol Neurodegener
. 2015 Sep;
10:44.
PMID: 26336937
Background: Alzheimer's disease (AD) is the most common form of dementia, the number of affected individuals is rising, with significant impacts for healthcare systems. Current symptomatic treatments delay, but do...
7.
Gabrielsson J, Hjorth S, Vogg B, Harlfinger S, Gutierrez P, Peletier L, et al.
Eur J Pharm Sci
. 2014 Dec;
67:144-159.
PMID: 25435491
Given the complexity of pharmacological challenge experiments, it is perhaps not surprising that design and analysis, and in turn interpretation and communication of results from a quantitative point of view,...
8.
Hofmann A, Kessler B, Ewerling S, Weppert M, Vogg B, Ludwig H, et al.
EMBO Rep
. 2003 Oct;
4(11):1054-60.
PMID: 14566324
Microinjection of DNA is now the most widespread method for generating transgenic animals, but transgenesis rates achieved this way in higher mammals are extremely low. To address this longstanding problem,...